Results of the FENopta study found that after one year of treatment, 96% of patients experienced no relapses of multiple sclerosis, with an annualized relapse rate of just 0.04.
Fenebrutinib Found Effective in Suppressing Relapsing Multiple Sclerosis Disease Activity
You May Also Like
Where can I buy Tobacco-Free Nicotine products?
February 27, 2025
Ozempic 用於什麼？
February 26, 2025
Global Launch Strategies in the Current Political Climate
February 19, 2025
+ There are no comments
Add yours